Nooka, A., Joseph, N., Dhodapkar, M., Gupta, V., Hofmeister, C., Rupji, M., Burton, B., Ahmed, H., Linton, D., Noga, S., Lin, T., Boise, L., Kaufman, J., Lonial, S. (2025). Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study. Blood. https://doi.org/10.1182/blood-2025-5843